Methsuximide
1 NDC across 1 manufacturer|0 Generic,1 Brand
Methsuximide is used to treat absence epilepsy, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved May 1, 2023. FDA's Orange Book lists 2 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $631K on Methsuximide across 1,622 claims for 264 beneficiaries.
Methsuximide is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $4.40 to $4.40 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$4.40 – $4.40
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Pfizer Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Anti-epileptic Agent class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing METHSUXIMIDE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
CELONTIN 300 MG CAPSULE | $4.4021 per EA | — |
Frequently Asked Questions
What is Methsuximide used to treat?
Methsuximide is used to treat absence epilepsy, per the National Library of Medicine's MED-RT classification.
When did Methsuximide become available as a generic?
FDA approved the first generic Methsuximide (ANDA) on May 1, 2023. The Orange Book currently lists 2 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Methsuximide?
In 2024, Medicare Part D spent $631K on Methsuximide across 1,622 claims for 264 beneficiaries.
How many Methsuximide products are on the market?
The Methsuximide drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Methsuximide?
NADAC reference prices for Methsuximide range from $4.4021 to $4.4021 per EA.
Which manufacturers make Methsuximide?
1 manufacturer lists Methsuximide in NADAC. Ranked by number of NDCs, the largest are Pfizer Inc. (1).